

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Breton Jose (Last) (First) (Middle) C/O BRICKELL BIOTECH, INC., 5777 CENTRAL AVENUE, SUITE 102 (Street) BOULDER, CO 80301 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 08/31/2019	3. Issuer Name and Ticker or Trading Symbol Brickell Biotech, Inc. [BBI]		
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Accounting Officer		5. If Amendment, Date Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,169	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options	09/22/2015	09/22/2025	Common Stock	1,726	\$ 12.17	D	
Stock Options	04/22/2015	04/22/2025	Common Stock	345	\$ 12.17	D	
Stock Options	12/23/2015	12/23/2025	Common Stock	1,380	\$ 12.17	D	
Stock Options	08/31/2016	08/31/2026	Common Stock	863	\$ 12.17	D	
Stock Options	12/15/2016	12/15/2026	Common Stock	2,589	\$ 12.17	D	
Stock Options	12/15/2018	12/15/2027	Common Stock	2,589	\$ 16.69	D	
Stock Options	12/15/2019	12/15/2028	Common Stock	5,178	\$ 16.45	D	
Stock Options	08/30/2020	08/30/2029	Common Stock	26,721	\$ 4.76	D	
Warrants	08/30/2019	08/30/2029	Common Stock	995	\$ 10.36	D	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

Breton Jose C/O BRICKELL BIOTECH, INC. 5777 CENTRAL AVENUE, SUITE 102 BOULDER, CO 80301			Chief Accounting Officer	
--	--	--	--------------------------	--

Signatures

/s/ Jose Breton		09/09/2019
**Signature of Reporting Person		Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.